tradingkey.logo
tradingkey.logo
Search

Globus Medical Inc

GMED
Add to Watchlist
78.288USD
-5.652-6.73%
Market hours ETQuotes delayed by 15 min
10.57BMarket Cap
18.02P/E TTM

More Details of Globus Medical Inc Company

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.

Globus Medical Inc Info

Ticker SymbolGMED
Company nameGlobus Medical Inc
IPO dateMar 08, 2012
CEOPfeil (Keith W)
Number of employees5300
Security typeOrdinary Share
Fiscal year-endMar 08
Address2560 General Armistead Ave
CityAUDUBON
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code19403
Phone16109301800
Websitehttps://www.globusmedical.com/
Ticker SymbolGMED
IPO dateMar 08, 2012
CEOPfeil (Keith W)

Company Executives of Globus Medical Inc

Name
Name/Position
Position
Shareholding
Change
Mr. David D. Davidar
Mr. David D. Davidar
Independent Director
Independent Director
685.24K
--
Mr. David C. Paul
Mr. David C. Paul
Executive Chairman of the Board
Executive Chairman of the Board
60.42K
+43.10%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
40.38K
+61.91%
Mr. Daniel J. Wolterman
Mr. Daniel J. Wolterman
Independent Director
Independent Director
24.02K
--
Ms. Leslie V. Norwalk
Ms. Leslie V. Norwalk
Independent Director
Independent Director
10.42K
--
Mr. Robert Andrew (Rob) Douglas
Mr. Robert Andrew (Rob) Douglas
Independent Director
Independent Director
2.00K
--
Mr. Daniel T. (Dan) Lemaitre
Mr. Daniel T. (Dan) Lemaitre
Independent Director
Independent Director
--
--
Mr. James R. Tobin
Mr. James R. Tobin
Independent Director
Independent Director
--
--
Mr. Stephen T. (Steve) Zarrilli
Mr. Stephen T. (Steve) Zarrilli
Independent Director
Independent Director
--
--
Mr. Keith W. Pfeil
Mr. Keith W. Pfeil
President, Chief Executive Officer
President, Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David D. Davidar
Mr. David D. Davidar
Independent Director
Independent Director
685.24K
--
Mr. David C. Paul
Mr. David C. Paul
Executive Chairman of the Board
Executive Chairman of the Board
60.42K
+43.10%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
40.38K
+61.91%
Mr. Daniel J. Wolterman
Mr. Daniel J. Wolterman
Independent Director
Independent Director
24.02K
--
Ms. Leslie V. Norwalk
Ms. Leslie V. Norwalk
Independent Director
Independent Director
10.42K
--
Mr. Robert Andrew (Rob) Douglas
Mr. Robert Andrew (Rob) Douglas
Independent Director
Independent Director
2.00K
--

FAQs

Who are the top five shareholders of Globus Medical Inc?

The top five shareholders of Globus Medical Inc are: Mr. David D. Davidar

How many institutions hold shares of Globus Medical Inc (GMED)?

As of 2026Q1, 1117 institutions hold shares of Globus Medical Inc, with a combined market value of approximately 115.75M, accounting for 85.62% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -17383594.00.

What is the biggest source of revenue for Globus Medical Inc?

In 2026Q1, the Musculoskeletal Solutions business generated the highest revenue for Globus Medical Inc, amounting to 2.80B and accounting for 95.20% of total revenue.
KeyAI